Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
EPHA2
Name:
EPH receptor A2
Location:
01p36.13
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | View | |
| NCT00796055 | Study of MEDI-547 to Evaluate the Safety Tolerability and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors | View | |
| NCT01591356 | EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors | View | |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | View | |
| NCT05198843 | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body | View | |
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | View | |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | View | |
| NCT05631899 | CAR-DC Vaccine and ICIs in Local AdvancedMetastatic Solid Tumors | View | |
| NCT03423992 | Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas | View | |
| NCT06456086 | Effect of Epstein-Barr Virus on Macrophage M2M1 Migration and EphA2 Expression in Adverse Drug Reactions | View | |
| NCT05283109 | ETAPA I Peptide-based Tumor Associated Antigen Vaccine in GBM | View | |
| NCT02252211 | Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers | View | |
| NCT00895960 | Dasatinib Plus Radiation TherapyTemozolomide in Newly-Diagnosed Glioblastoma | View |